(1) high levels of alanine aminotransferase (also known as glutamate aminotransferase ALT) and/or aspartate aminotransferase (also known as glutamate aminotransferase AST) before treatment (this is very important, in general, the efficacy of interferon is proportional to the serum aminotransferase level, that is, if the aminotransferase is normal before treatment, interferon is often ineffective or has poor efficacy) (2) low viral load, HBV DNA < 2×108 copies/ml; (3) female; (4) short duration of disease; (5) non-maternal-to-child transmission; (6) heavy inflammation and necrosis of liver tissue, and light fibrosis (only known by liver biopsy, most patients do not undergo liver biopsy, this article is for reference only); (7) good compliance with treatment; (8) good compliance with treatment (8) No co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV); (9) HBV gene is type A (most hospitals are not yet equipped to perform genotyping of hepatitis B virus); (10) Good response to treatment, i.e. serum HBVDNA is not detectable at 12 or 24 weeks of treatment. Among the above, ALT (and/or AST), HBV DNA level and HBV genotype before treatment are the three important factors to predict the efficacy. In fact, most hospitals are not yet equipped to test for HBV genotype, so the first two of these are the most important.